Hormone Sensitive Metastatic Disease: Tumor Boards

This course is available as part of the 2016 ASCO Tumor Boards bundle.

This is a case-based activity that includes discussion of a 36-year-old woman who originally presented at 18 weeks gestation with clinical T2N0, grade 3 invasive ductal carcinoma of the right breast. The tumor was ER+, PR+, and HER2 negative.

At the end of this course, participants should understand:

  1. Explain how to incorporate recent evidence-based guideline recommendations and new data to select first-line therapy for women with hormone sensitive advanced breast cancer
  2. Describe the evolving role of ovarian suppression in the treatment of premenopausal women with early or advanced hormone sensitive breast cancer

IMPORTANT NOTE: This course expires on October 28, 2019. Participants must complete all necessary course components by this date.